Rankings
▼
Calendar
TSHA Q4 2022 Earnings — Taysha Gene Therapies, Inc. Revenue & Financial Results | Market Cap Arena
TSHA
Taysha Gene Therapies, Inc.
$1B
Q4 2022 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$3M
Gross Profit
$823,000
32.9% margin
Operating Income
-$19M
-747.4% margin
Net Income
-$56M
-2227.1% margin
EPS (Diluted)
$-0.99
QoQ Revenue Growth
+Infinity%
Cash Flow
Operating Cash Flow
$14M
Free Cash Flow
$12M
Stock-Based Comp.
$4M
Balance Sheet
Total Assets
$126M
Total Liabilities
$125M
Stockholders' Equity
$949,000
Cash & Equivalents
$88M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$3M
$0
—
Gross Profit
$823,000
$0
—
Operating Income
-$19M
-$50M
+62.4%
Net Income
-$56M
-$50M
-10.6%
← FY 2022
All Quarters
Q1 2023 →